Multicenter randomized phase II study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases (YCOG1001).
Mayumi OzawaJun WatanabeAtsushi IshibeKoki GotoYoshiro FujiiKazuya NakagawaYusuke SuwaHirokazu SuwaHidenobu MasuiMitsutaka SugitaYasuhisa MochizukiShigeru YamagishiSeiji HasegawaYuki HommaMasashi MomiyamaTakafumi KumamotoRyusei MatsuyamaKazuhisa TakedaMasataka TaguriItaru EndoPublished in: Cancer chemotherapy and pharmacology (2024)
SOX regimens as adjuvant therapy after hepatectomy for CRCLM had high rates of discontinuation due to toxicity in both groups. In particular, the RDI of S-1 was < 50%. Therefore, the SOX regimen is not recommended as adjuvant chemotherapy after hepatectomy for CRCLM.